Alzamend Neuro is expected to release its earnings report on Wednesday, December 10, 2023, prior to the market opening. Analysts project the company will report an earnings loss of $0.83 per share for the recent quarter. As a clinical-stage biopharmaceutical firm, Alzamend Neuro focuses on developing innovative treatments for neurodegenerative and psychiatric disorders.
On Monday, the company’s stock opened at $2.25, reflecting a year low of $1.88 and a year high of $12.06. The stock’s performance has shown fluctuations, with a 50-day moving average at $2.33 and a 200-day moving average at $2.66. Currently, Alzamend Neuro holds a market capitalization of $7.07 million, a price-to-earnings (P/E) ratio of -0.34, and a beta of -0.25.
Recent Insider Activity
In a notable transaction, Director Milton C. Ault III sold 101,394 shares of Alzamend Neuro on October 8, 2023. The shares were sold at an average price of $2.44, totaling approximately $247,401.36. Following this sale, Ault’s direct ownership of the company’s stock declined to 28,657 shares, valued at around $69,923.08. This sale indicates a significant reduction in Ault’s stake, representing a 77.96% decrease.
In the past three months, insiders have collectively sold 661,233 shares worth $1,584,153. Currently, insiders own 30.21% of Alzamend Neuro’s stock.
Company Overview and Future Prospects
According to the company’s profile, Alzamend Neuro, Inc. is in the early stages of clinical development, with a pipeline that includes promising candidates. One of its key products, AL001, combines lithium, proline, and salicylate aimed at treating conditions such as Alzheimer’s disease, bipolar disorder, post-traumatic stress disorder, and major depressive disorder. Another innovative approach is represented by ALZN002, which utilizes a mutant-peptide sensitized cell as a therapeutic vaccine, targeting the restoration of the immune system’s ability to combat Alzheimer’s.
As the company prepares for its earnings report, market observers will be closely monitoring these developments to gauge Alzamend Neuro’s progress in the biopharmaceutical sector.
